Document:

Form of Subscription Agreement

 Exhibit 10.1 
  
 SeraCare Life Sciences, Inc. 
  

SUBSCRIPTION AGREEMENT 
  
 June    , 2004 
  
 TO EACH OF THE PURCHASERS 
 NAMED ON THE SIGNATURE 
 PAGES HEREOF 
  
 Ladies and Gentlemen: 
  
 SeraCare
Life Sciences, Inc., a California corporation (the “Company”), hereby confirms its agreement with each of you (each a “Purchaser” and, collectively, the “Purchasers”), as set forth below.

  
 1. The Shares. Subject to the terms and conditions
herein contained, the Company agrees to issue and sell to each Purchaser a number of shares of its Common Stock, no par value (the “Common Stock”), as set forth on the counterpart signature page of such Purchaser hereto
(collectively for all Purchasers, the “Shares”). 
  
 The Shares will be offered and sold to the Purchasers without such offers and sales being registered under the Securities Act of 1933, as amended (together with the rules and regulations of the Securities and Exchange Commission (the
“Commission”) promulgated thereunder, the “Securities Act”), in reliance on exemptions therefrom. 
  
 In connection with the sale of the Shares, the Company has made available its periodic reports filed with the Commission under the Securities Exchange Act
of 1934, as amended (together with the rules and regulations of the Commission promulgated thereunder, the “Exchange Act”) since October 1, 2003 and prior to the date hereof. These reports and filings are collectively referred to as
the “Disclosure Documents”. All references in this Agreement to financial statements and schedules and other information which is “contained,” “included” or “stated” in the Disclosure Documents (or
other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information, which is incorporated by reference in the Disclosure Documents. 
  
 The Purchasers will be entitled to the benefits of the Registration Rights
Agreement, in the form of Exhibit A hereto, to be dated as of the date hereof among the parties hereto (the “Registration Rights Agreement”) pursuant to which the Company has agreed, among other things, to file a resale
registration statement (the “Registration Statement”) under the Securities Act covering the resale of the Shares by holders thereof. 

 The Registration Rights Agreement and this Agreement are herein collectively referred to as the
“Basic Documents”. 
  
 2. Representations and
Warranties of the Company. The Company represents and warrants to and agrees with each Purchaser that: 
  
 (a) The Company has timely filed all reports required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section
13(a) or 15(d) thereof, for the twelve months preceding the date hereof. The Disclosure Documents as of their respective dates did not, and any amendment or supplement thereto as of its date did not, contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Disclosure Documents, at the time they were filed with the Commission, complied in all
material respects with the requirements of the Securities Act and/or the Exchange Act, as the case may be (collectively, the “Securities Acts”), as applicable. 
  
 (b) The Company has been duly incorporated and is validly existing in good standing as a corporation under the laws of the
State of California, with the requisite corporate power and authority to own its properties and conduct its business as now conducted as described in the Disclosure Documents and is duly qualified to do business as a foreign corporation in good
standing in all other jurisdictions where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified would not have (i) a material adverse effect on the
business, financial condition or results of operations of the Company, (ii) a material adverse effect on the legality, validity or enforceability of any Basic Document, or (iii) a material impairment to the Company’s ability to perform on a
timely basis its obligations under any Basic Document (any such event in (i), (ii) or (iii), a “Material Adverse Effect”). 
  
 (c) The Company has the requisite corporate power and authority to execute, deliver and perform its obligations under the Basic Documents. Each of the
Basic Documents has been duly and validly authorized by the Company and, when executed and delivered by the Company, will constitute a valid and legally binding agreement of the Company, enforceable against the Company in accordance with its terms
except as (i) the enforcement thereof may be limited by (A) bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or other similar laws now or hereafter in effect relating to or affecting creditors’ rights generally or (B)
general principles of equity and the discretion of the court before which any proceeding therefore may be brought (regardless of whether such enforcement is considered in a proceeding at law or in equity) and (ii) any rights to indemnity, or
contribution under the Registration Rights Agreement may be limited by federal and state securities laws and public policy considerations (collectively, the “Enforceability Exceptions”). 
  

 2 

 (d) The Shares have been duly authorized and, when issued upon payment thereof in accordance with this
Agreement, will have been validly issued, fully paid and nonassessable and shall be free and clear of all encumbrances and restrictions (other than those created by the Purchasers), except for restrictions on transfer set forth in the Basic
Documents or imposed by applicable securities laws. The capital stock of the Company, including the Common Stock, conforms to the description thereof contained in the Disclosure Documents. 
  
 (e) No consent, approval, authorization, license, qualification, exemption
or order of any court or governmental agency or body or third party is required for the execution, delivery or performance of the Basic Documents by the Company or for the consummation by the Company of any of the transactions contemplated thereby,
except for such consents, approvals, authorizations, licenses, qualifications, exemptions or orders (i) as will have been obtained on or prior to the Closing, (ii) as are required from the Commission to cause the Registration Statement to be
declared effective under the Securities Act, or (iii) the failure to obtain which would not have a Material Adverse Effect. 
  
 (f) The execution, delivery and performance by the Company of the Basic Documents and the consummation by the Company of the transactions contemplated
thereby and the fulfillment of the terms thereof will not (a) violate, conflict with or constitute or result in a breach of or a default under (or an event that, with notice or lapse of time, or both, would constitute a breach of or a default under)
any of (i) the terms or provisions of any material contract, indenture, mortgage, deed of trust, loan agreement, note, lease, license, franchise agreement, permit, certificate or agreement or instrument to which the Company is a party, (ii) the
articles of incorporation or bylaws of the Company, or (iii) any statute, judgment, decree, order, rule or regulation of any court, governmental agency, stock market or trading facility on which the Common Stock trades or on which the Company has
applied for listing to trade or other body applicable to the Company or (b) result in the imposition of any lien upon or with respect to any of the material properties or assets now owned by the Company; which violation, conflict, breach, default or
lien (with respect to any of clauses (a) or (b) of this Section 2(f) other than (a)(ii)) would have a Material Adverse Effect. 
  
 (g) The audited financial statements included in the Disclosure Documents present fairly the financial position, results of operations, cash flows and
changes in stockholders’ equity of the Company, at the dates and for the periods to which they relate and have been prepared in accordance with generally accepted accounting principles applied on a consistent basis. The interim unaudited
consolidated financial statements included in the Disclosure Documents present fairly the consolidated financial position, results of operations and cash flows of the Company, at the dates and for the periods to which they relate, subject

  

 3 

 to year-end audit adjustments, and have been prepared in accordance with generally accepted accounting principles applied
on a consistent basis with the audited consolidated financial statements included therein. 
  
 (h) Except as described in the Disclosure Documents, there is not pending or, to the best knowledge of the Company, threatened any action, suit, proceeding, inquiry or investigation, governmental or otherwise, to
which the Company is a party, before or brought by any court, arbitrator or governmental agency or body, that, if determined adversely to the Company, would have a Material Adverse Effect. 
  
 (i) The Company is not, and immediately after the Closing Date will not be,
required to register as an “investment company” or a company “controlled by” an “investment company” within the meaning of the Investment Company Act of 1940, as amended (the “Investment Company Act”).

  
 (j) None of the Company or any of its Affiliates (as defined
in Rule 501(b) of Regulation D under the Securities Act) has directly, or through any agent, (i) sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of any “security” (as defined in the Securities Act) which
is or could be integrated with the sale of the Shares in a manner that would require the registration under the Securities Act of the issuance of the Shares pursuant to the Basic Documents or (ii) engaged in any form of general solicitation or
general advertising (as those terms are used in Regulation D under the Securities Act) in connection with the offering of the Shares or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act. Assuming the
accuracy of the representations and warranties of the Purchasers in Section 8 hereof, it is not necessary in connection with the offer, sale and delivery of the Shares to the Purchasers in the manner contemplated by this Agreement to register any of
the Shares under the Securities Act. 
  
 (k) Except as described
in the engagement letter dated June 8, 2004 with First Equity Capital Securities, Inc., no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other third person with respect to the transactions contemplated by this Agreement. 
  
 3. Agreement to Sell and Purchase the Shares. 
  
 (a) Subject to the terms of this Agreement, at the Closing (as defined in Section 4(b)), the Company agrees to sell to each Purchaser, and each Purchaser
agrees to purchase from the Company, the number of Shares set forth on Purchaser’s counterpart execution page hereof, at a purchase price of $10.20 per Share. 
  

 4 

 (b) Each Purchaser shall severally, and not jointly, be liable for only the purchase of the number of
Shares set forth on Purchaser’s counterpart execution page hereof. The Company’s agreement with each of the Purchasers is a separate agreement, and the sale of Shares to each of the Purchasers is a separate sale and the Company’s
obligation to sell the Shares to one Purchaser is not conditioned on the performance of this Agreement by any other Purchaser. The obligations of each Purchaser hereunder are expressly not conditioned on the purchase by any or all of the other
Purchasers of the Shares such other Purchasers have agreed to purchase. 
  
 (c) Each Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept or reject, in whole or in part, any proposed purchase of Shares. The Company shall have no obligation
hereunder with respect to any Purchaser until the Company shall execute and deliver to such Purchaser an executed copy of this Agreement. If this Agreement is not executed and delivered by the Company or the offering is terminated, this Agreement
shall be of no further force and effect. 
  
 (d) The obligations
of each Purchaser under any Basic Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Basic
Document. The decision of each Purchaser to purchase Shares pursuant to the Basic Documents has been made by such Purchaser independently of any other Purchaser. Nothing contained herein or in any Basic Document, and no action taken by any Purchaser
pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by the Basic Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no other Purchaser will
be acting as agent of such Purchaser in connection with monitoring its investment in the Shares or enforcing its rights under the Basic Documents. 
  
 4. Escrow of Purchase Price; Closing; Delivery of Shares at Closing. 
  
 (a) Concurrently with its execution of this Agreement, each Purchaser shall deliver to Wells Fargo Bank, N.A., as escrow
agent (the “Escrow Agent”), by wire transfer to the account specified in Exhibit B, the purchase price under the heading “Total Investment Amount” as set forth on Purchaser’s counterpart execution page hereof.
All such amounts shall be held in escrow pending the Closing (as defined below) or earlier termination of this Agreement, as provided in the escrow agreement to be entered into between the Company, First Equity Capital Securities, Inc. and Escrow
Agent, the form of which is attached hereto as Exhibit C. 
  
 (b) The closing of the purchase and sale of the Shares pursuant to this Agreement (the “Closing”) shall be held at 10:00 a.m. (Pacific Time) on the Business Day 
  

 5 

 following the date (the “Closing Date”) that all of the conditions to closing set forth in Section 6 and
Section 7 have been satisfied or waived by the party in whose favor such conditions run, at the offices of O’Melveny & Myers LLP, located at 114 Pacifica, Suite 100, Irvine, California, or on such other date and place as may be agreed to by
the Company and the Purchasers. 
  
 (c) At the Closing, (1) the
Company shall deliver to each Purchaser (i) stock certificates registered in the name of such Purchaser, or in such nominee name(s) as designated by such Purchaser, representing the Shares to be purchased by such Purchaser at the Closing, and (ii)
an executed Registration Rights Agreement, and (2) the Escrow Agent shall deliver to the Company on behalf of each Purchaser the purchase price under the heading “Total Investment Amount” as set forth on Purchaser’s counterpart
execution page hereof by wire transfer of immediately available funds to the account of the Company designated to it by the Company in writing (less the 6.0% cash commission due to First Equity Capital Securities, Inc., which shall be released
directly by the Escrow Agent to First Equity Capital Securities, Inc.). The name(s) in which the stock certificates are to be issued to each Purchaser as well as the number and type of Shares to be purchased by each Purchaser are set forth in the
Purchaser’s counterpart execution page hereto, as completed by each Purchaser. 
  
 5. Nasdaq Notification and Additional Listing Form. The Company covenants and agrees with each Purchaser that it will use its commercially reasonable efforts to cause the Shares to be included for listing on
the Nasdaq National Market. 
  
 6. Conditions of the
Purchasers’ Obligations. The obligation of each Purchaser to purchase and pay for the Shares is subject to the following conditions unless waived in writing by the relevant Purchaser: 
  
 (a) The issuance and sale of the Shares pursuant to this Agreement shall
not be enjoined (temporarily or permanently) and no restraining order or other injunctive order shall have been issued in respect thereof. 
  
 (b) On or before the Closing Date, the Purchasers shall have received the Registration Rights Agreement executed by the Company. 
  
 (c) The closing of the asset acquisition contemplated by that certain Asset
Purchase Agreement, dated April 16, 2004, between the Company, Boston Biomedica, Inc. and BBI Biotech Research Laboratories, Inc. (the “BBI Acquisition”) shall have occurred. 
  
 7. Conditions of the Company’s Obligations. The obligation of the
Company to issue the Shares is subject to the following condition unless waived in writing by the Company: 
  
 (a) The issuance and sale of the Shares pursuant to this Agreement shall not be enjoined (temporarily or permanently) and no restraining order or other
injunctive order shall have been issued in respect thereof. 
  

 6 

 (b) On or before the Closing Date, the Company shall have received the Registration Rights Agreement
executed by the applicable Purchaser. 
  
 (c) The closing of the
BBI Acquisition shall have occurred. 
  
 8. Representations and
Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants to the Company as follows 
  
 (a) The Shares to be acquired by it hereunder are being acquired for its own account for investment (and/or on behalf of managed accounts who are
purchasing solely for their own accounts for investment) and with no intention of distributing or reselling such Shares or any part thereof or interest therein in any transaction which would be in violation of the securities laws of the United
States of America or any State, without prejudice, however, to such Purchaser’s right, subject to the provisions of this Agreement and the Registration Rights Agreement, to sell or otherwise dispose of all or any part of the Shares, including
the Shares or Warrant Shares under an effective registration statement under the Securities Act and in compliance with applicable state securities laws or under an exemption from such registration. 
  
 (b) Such Purchaser understands that the Shares have not been registered
under the Securities Act and may not be offered, resold, pledged or otherwise transferred except (a) pursuant to an exemption from registration under the Securities Act (and, if requested by the Company, based upon an opinion of counsel acceptable
to the Company) or pursuant to an effective registration statement under the Securities Act and (b) in accordance with all applicable securities laws of the states of the United States. 
  
 Each Purchaser agrees to the imprinting, so long as required under this Section, of the following legend on the Shares:

  
 The shares of common stock evidenced by this certificate
have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered, sold, pledged or otherwise transferred (“transferred”) in the absence of such registration or an applicable exemption therefrom. In the
absence of such registration, such shares may not be transferred unless (i) such transfer complies with the requirements of rule 144(k) or (ii), if the Company requests, the Company has received a written opinion from counsel in form and substance
satisfactory to the Company stating that such transfer is being made in compliance with all applicable federal and state securities laws. 
  

 7 

 The legend set forth above will be removed if and when (i) the Shares are disposed of pursuant to an
effective registration statement under the Securities Act, (ii) the Shares become available for resale under Rule 144(k) under the Securities Act, or (iii) in the opinion of counsel to the Company experienced in the area of United States federal
securities laws such legends are no longer required under applicable requirements of the Securities Act. Each Purchaser for itself and no other Purchaser agrees that, in connection with any transfer of Shares by it pursuant to an effective
registration statement under the Securities Act, such Purchaser will comply with the prospectus requirements under the Securities Act applicable to such transfer The Company makes no representation, warranty or agreement as to the availability of
any exemption from registration under the Securities Act with respect to any resale of Shares. 
  
 (c) Such Purchaser is an accredited investor within the meaning of Rule 501(a) of Regulation D under the Securities Act and has provided the Company with
a complete and accurate questionnaire documenting the basis for this representation. Such Purchaser is acquiring the Shares in the ordinary course of its business. Such Purchaser does not have any agreement or understanding, directly or indirectly,
with any person to distribute any of the Shares. 
  
 (d) Such
Purchaser has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, such Purchaser having been represented by counsel, and
has so evaluated the merits and risks of such investment and is able to bear the economic risk of such investment and, at the present time, is able to afford a complete loss of such investment. 
  
 (e) The purchase of the Shares to be purchased by it has been duly
authorized by such Purchaser and each of this Agreement and Registration Rights Agreement has been duly executed and delivered by it or on its behalf and constitutes the valid and legally binding obligation of such Purchaser, enforceable against the
Purchaser in accordance with its terms, subject to the Enforceability Exceptions. 
  
 (f) Each Purchaser, severally and not jointly and as to itself only, represents and warrants to the Company that neither it nor any of its directors, officers, employees, agents, or controlling persons has taken,
directly or indirectly, any actions designed, or might reasonably be expected to cause or result, under the Securities Acts or otherwise, in, or that has constituted, stabilization, or manipulation of the price of the Shares. 
  
 (g) Each Purchaser acknowledges that it has had an opportunity to review the
Disclosure Documents and further acknowledges that it has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Shares and the merits and risks of investing in the Shares; (ii) access to information about the 
  

 8 

 Company and the Company’s financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment in the Shares; and (iii) the opportunity to obtain such additional information which the Company possesses or can acquire without unreasonable effort or expense that is necessary to verify the
accuracy and completeness of the information contained in the Disclosure Documents. 
  
 (h) Each Purchaser further acknowledges that the Company is engaged in the following transactions or potential transactions: (i) the Company has entered into an asset purchase agreement with respect to the BBI
Acquisition, but makes no assurances as to the timing or completion of that transaction (a copy of the asset purchase agreement for the BBI Acquisition (the “Asset Purchase Agreement”) is filed as an exhibit to the Company’s
Report of Form 8-K, filed with the Commission on April 16, 2004); (ii) the Company has entered into an asset purchase agreement, dated as of June 3, 2004, with Genomics Collaborative, Inc., a Delaware corporation, pursuant to which the Company
acquired substantially all of the assets of Genomics Collaborative, Inc. for a combination of stock, cash and the assumption of certain liabilities, and agreed to register the resale of those securities by Genomics Collaborative, Inc. and/or certain
permitted transferees of Genomics Collaborative, Inc.; and (iii) the Company considers and reviews other acquisition opportunities from time to time and reserves the right to pursue any such opportunity in its sole discretion. 
  
 (i) Such Purchaser understands and acknowledges that (i) the Shares are
offered and sold without registration under the Securities Act in a private placement that is exempt from the registration provisions of the Securities Act and (ii) the availability of such exemption depends in part on, and that the Company and its
counsel will rely upon, the accuracy and truthfulness of the foregoing representations and such Purchaser hereby consents to such reliance. 
  
 (j) The purchase by such Purchaser of the Shares issuable to it at the Closing will not result in such Purchaser (individually or together with any other
person(s) with whom such Purchaser has identified, or will have identified, itself as part of a “group” in a public filing made with the Commission involving the Company’s securities) acquiring, or obtaining the right to acquire, in
excess of 19.999% of the Common Stock or the voting power of the Company on a post transaction basis that assumes that the Closing shall have occurred. Such Purchaser does not presently intend to, alone or together with others, make a public filing
with the Commission to disclose that it has (or that it together with such other persons have) acquired, or obtained the right to acquire, as a result of the Closing (when added to any other securities of the Company that it or they then own or have
the right to acquire), in excess of 19.999% of the Common Stock or the voting power of the Company on a post transaction basis that assumes that the Closing shall have occurred. 
  
 (k) Such Purchaser has independently evaluated the merits of its decision to purchase Shares pursuant to this Agreement,
such decision has been independently 
  

 9 

 made by such Purchaser and such Purchaser confirms that it has only relied on the advice of its own business and/or legal
counsel and not on the advice of any other Purchaser’s business and/or legal counsel or advisors in making such decision. Such Purchaser has not relied on the truth, accuracy or completeness of the statements contained in any research report
concerning the Company that was prepared by an investment banking firm. 
  
 9. Termination. 
  
 (a) Unless the Closing has
first occurred, this Agreement shall terminate on the earlier to occur of (i) the termination of the Asset Purchase Agreement or (ii) September 30, 2004, provided that if the BBI Acquisition has not been closed or terminated by September 30, 2004,
the Purchasers may, by the written consent of Purchasers representing a two-thirds majority of the Shares, extend the termination date provided in this clause (ii). Except as provided in Section 9(b), upon termination of this Agreement pursuant to
this Section 9(a), neither the Company nor any of the Purchasers shall have any obligation to the other under this Agreement. 
  
 (b) Nothing in this Section 9 shall be deemed to release any party from any liability for any breach (prior to termination of this Agreement) by such
party of the terms and provisions of this Agreement. 
  
 10.
Notices. All communications hereunder shall be in writing and, (i) if sent to a Purchaser, shall be hand delivered, mailed by first-class mail, couriered by next-day air courier or sent by facsimile to their address and/or facsimile number on
their signature page hereof and (ii) if sent to the Company, shall be hand delivered, mailed by first-class mail, couriered by next-day air courier or sent by facsimile to: 
  
 SeraCare Life Sciences, Inc. 
 1935 Avenida del Oro, Suite F 
 Oceanside, CA 92056 
 Attention: President 
 Facsimile number: (760)
806-8933 
  
 with a copy to: 
  
 O’Melveny & Myers LLP 
 114 Pacifica, Suite 100 
 Irvine, California
92618 
 Attention: Andor D. Terner, Esq. 
 Facsimile Number: (949) 737-2300 
  
 All such notices and
communications shall be deemed to have been duly given: when delivered by hand, if personally delivered; three days after being deposited in the mail, 
  

 10 

 postage prepaid, if mailed; one business day after being timely delivered to a national recognized overnight courier; and
upon receipt of a mechanically generated answer-back if sent by facsimile. 
  
 11. Successors. This Agreement shall inure to the benefit of and be binding upon each Purchaser and the Company and their respective permitted successors and legal representatives, and nothing expressed or
mentioned in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions herein contained. This Agreement and all conditions and
provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person. The Purchasers may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Company. 
  
 12. No Waiver; Modifications in
Writing. No failure or delay on the part of the Company or any Purchaser in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude
any other or further exercise thereof or the exercise of any other right, power or remedy. The remedies provided for herein are cumulative and are not exclusive of any remedies that may be available to the Company or any Purchaser at law or in
equity or otherwise. No waiver of or consent to any departure by the Company or any Purchaser from any provision of this Agreement shall be effective unless signed in writing by the party entitled to the benefit thereof, provided that notice of any
such waiver shall be given to each party hereto as set forth below. No provision of this Agreement may be amended except in a written instrument signed by the Company and the Purchasers holding (or prior to the Closing, obligated to purchase) a
majority of the Shares. Any amendment, supplement or modification of or to any provision of this Agreement, any waiver of any provision of this Agreement, and any consent to any departure by the Company or any Purchaser from the terms of any
provision of this Agreement shall be effective only in the specific instance and for the specific purpose for which made or given. Except where notice is specifically required by this Agreement, no notice to or demand on the Company in any case
shall entitle the Company to any other or further notice or demand in similar or other circumstances. 
  
 13. Certain Legal Fees. Each Purchaser and the Company shall pay the fees and expenses of its own respective advisers, counsel, accountants and
other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of the Basic Documents. 
  
 14. Entire Agreement. This Agreement, along with the other Basic Documents constitutes the entire agreement among the
parties hereto and supersedes all prior agreements, understandings and arrangements, oral or written, among the parties hereto with respect to the subject matter hereof. 
  

 11 

 15. APPLICABLE LAW. THE VALIDITY AND INTERPRETATION OF THIS AGREEMENT, AND THE TERMS AND
CONDITIONS SET FORTH HEREIN SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, WITHOUT GIVING EFFECT TO PROVISIONS RELATING TO CONFLICTS OF LAW TO THE EXTENT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION
WOULD BE REQUIRED THEREBY. IF A PURCHASER SHALL COMMENCE A PROCEEDING AGAINST THE COMPANY, OR IF THE COMPANY SHALL COMMENCE A PROCEEDING AGAINST A PURCHASER, TO ENFORCE ANY PROVISIONS OF A BASIC DOCUMENT, THEN THE PREVAILING PARTY IN SUCH PROCEEDING
SHALL BE REIMBURSED BY THE OTHER PARTY FOR ITS ATTORNEY’S FEES AND OTHER COSTS AND EXPENSES INCURRED WITH THE INVESTIGATION, PREPARATION AND PROSECUTION OF SUCH PROCEEDING. 
  
 16. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION
WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
  
 17. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 12 

 If the foregoing correctly sets forth our understanding, please indicate your acceptance thereof by signing the
counterpart signature page attached hereto. 
  

			
	Very truly yours,
	
	SERACARE LIFE SCIENCES, INC.
		
	By:	 	  

	 	 	Name:
	 	 	Title:
	Date:	 	 July 9, 2004

  

 13 

 SUBSCRIPTION AGREEMENT SIGNATURE PAGE 
  
 Accepted and Agreed: 
  

			
	  

	 	Total Investment Amount:$ __________________
	Name of Purchaser (Print)	 	Total Number of Shares: ____________________

  

							
	By:	 	  

			
	 	 	Name:	 	  

			
	 	 	Title:	 	  

  

			
	Date:	 	  

		
	Address:	 	  

		
	 	 	  

		
	 	 	  

		
	Telephone:	 	  

		
	Facsimile:	 	  

  
  
 Please register Shares as follows: 
  

			
	Name:	 	  

		
	 	 	  

		
	 	 	  

  
 Tax I.D. Number of Person in whose
name the Shares are to be registered: 
  
 __________________________________________________ 
  

 14 

 Exhibit A 
  

Form of Registration Rights Agreement 
  
 [Attached Hereto] 

 SERACARE LIFE SCIENCES, INC. 
  
 Subscription Agreement 
  

List of Purchasers 
  

					
	 	  	 Name of Purchaser

	  	Total Investment
Amount*

	1.	  	Marshall M. Becker	  	$51,000
	2.	  	Stanley S. Becker	  	$51,000
	3.	  	Murray Blitstein	  	$25,500
	4.	  	Anthony Cappiello	  	$51,000
	5.	  	Castlerigg Master Investments Ltd.	  	$510,000
	6.	  	Catalysis Partners, LLC	  	$510,000
	7.	  	Scott DeGhetto	  	$102,000
	8.	  	EL Equities, LLC	  	$510,000
	9.	  	Bernard R. Feingold	  	$81,600
	10.	  	Robert Graifman	  	$92,820
	11.	  	Michael Groveman	  	$51,000
	12.	  	Geoffrey M. Haar	  	$153,000
	13.	  	William M. Hitchcock	  	$510,000
	14.	  	Linda Jacobson	  	$81,600
	15.	  	James G. Kreissman	  	$234,600
	16.	  	Robert S. Krieger	  	$44,880
	17.	  	Joan B. Levine	  	$25,500
	18.	  	Kenneth R. Levine	  	$178,500

					
	 	  	 Name of Purchaser

	  	Total Investment
Amount*

	19.	  	J.E. McConnaughy Jr.	  	$204,000
	20.	  	New Dimensions Trading Limited	  	$3,570,000
	21.	  	Provco Ventures I, LP	  	$255,000
	22.	  	Stager Partners LP	  	$510,000
	23.	  	The Lincoln Fund, L.P.	  	$255,000
	24.	  	Joshua Winkler	  	$102,000

	*	At a price per share equal to $10.20.Form of Registration Rights Agreement

 Exhibit 10.2 
  
 SeraCare Life Sciences, Inc. 
  

Registration Rights Agreement 
  
 June    , 2004 
  
 TO EACH OF THE PURCHASERS 
 NAMED ON THE SIGNATURE PAGES 
 HEREOF 
  
 Ladies and Gentlemen: 
  
 SeraCare Life Sciences, Inc., a
California corporation (the “Company”), proposes to issue and sell to the Purchasers (as defined herein) upon the terms set forth in the Subscription Agreement (as defined herein) shares (the “Shares”) of its common
stock, no par value (the “Common Stock”). As an inducement to the Purchasers to enter into the Subscription Agreement and in satisfaction of a condition to the obligations of the Purchasers thereunder, the Company agrees with each
Purchaser as follows: 
  
 1. Definitions. 
  
 (a) Capitalized terms used herein without definition shall have the meanings
ascribed thereto in the Subscription Agreement. As used in this Agreement, the following defined terms shall have the following meanings: 
  
 “Affiliate” of any specified person means any other person which, directly or indirectly, is in control of, is controlled by, or is under
common control with such specified person. For purposes of this definition, control of a person means the power, direct or indirect, to direct or cause the direction of the management and policies of such person whether by contract or otherwise; and
the terms “controlling” and “controlled” have meanings correlative to the foregoing. 
  
 “Business Day” means each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which banking institutions in Orange
County, California are authorized or obligated by law or executive order to close. 
  
 “Closing Date” has the meaning in the Subscription Agreement. 
  
 “Closing Price” as of any date means the closing price of one share of Common Stock as reported by the Nasdaq National Market (or, if not
then listed on the Nasdaq National Market, then on the Nasdaq SmallCap Market or the OTCBB, as applicable) on such date. 

 “Commission” means the United States Securities and Exchange Commission, or any other
federal agency at the time administering the Exchange Act or the Securities Act, whichever is the relevant statute for the particular purpose. 
  
 “Common Stock” means the Company’s common stock, no par value per share. 
  
 “Delay Conditions” means (i) the Company is in possession of
material non-public information the disclosure of which would have a material adverse effect on the business, financial condition or results of operations of the Company or (ii) the Board of Directors of the Company determines in good faith that as
a result of the occurrence or existence of any pending corporate development with respect to the Company, a failure by the Company to cause (A) the Shelf Registration Statement ceasing to be effective, or (B) a Prospectus thereunder ceasing to be
usable, as the case may be, would have a material adverse effect on the business, financial condition or results of operations of the Company. The Delay Conditions shall be deemed to no longer exist if (x) in the case of clause (i) above, the Board
of Directors of the Company determines in good faith that the disclosure of such material information would not be prejudicial to or contrary to the interest of the Company and (y) in the case of clause (ii) above, the Board of Directors of the
Company determines in good faith that such delay or cessation is no longer appropriate. 
  
 “Effectiveness Period” has the meaning assigned thereto in Section 2(c) hereof. 
  
 “Effective Time” means the date on which the Commission declares the Shelf Registration Statement effective or on which the Shelf
Registration Statement otherwise becomes effective. 
  
 “Electing Holder” has the meaning assigned thereto in Section 3(a) hereof. 
  
 “Exchange Act” means the United States Securities Exchange Act of 1934, as amended. 
  
 “Filing Deadline Date” means the 90th day immediately following the Closing Date. 
  
 “holder” means, when used with respect to any Security, the record holder of such Security. 
  
 “NASD Rules” means the Rules of the National Association of
Securities Dealers, Inc., as amended from time to time. 
  
 “Notice and Questionnaire” means a Notice of Registration Statement and Selling Securityholder Questionnaire, substantially in the form of Exhibit A attached hereto, relating to the Securities. 
  
 “person” means an individual, partnership, corporation,
limited liability company, trust or unincorporated organization, or a government or agency or political subdivision thereof. 
  

 2 

 “Prospectus” means the prospectus (including, without limitation, any preliminary
prospectus, any final prospectus and any prospectus that discloses information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A under the Securities Act) included in the Shelf
Registration Statement, as amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by the Shelf Registration Statement and by all other amendments and
supplements to such prospectus, including all material incorporated by reference in such prospectus and all documents filed after the date of such prospectus by the Company under the Exchange Act and incorporated by reference therein. 
  
 “Purchasers” means the Purchasers named on the signature
pages of the Subscription Agreement. 
  
 “Registrable
Securities” means all or any portion of the Securities; provided, however, that a security ceases to be a Registrable Security when it is no longer a Restricted Security. 
  
 “Restricted Security” means any Security except any such
Security that (i) the resale of which has been registered pursuant to an effective registration statement under the Securities Act and sold in a manner contemplated by the Shelf Registration Statement, (ii) has been transferred in compliance with
Rule 144 under the Securities Act (or any successor provision thereto) such that after such transfer the transferred securities are no longer “restricted securities” as such term is defined under Rule 144, or is transferable pursuant to
paragraph (k) of Rule 144 (or any successor provision thereto) or (iii) has otherwise been transferred and a new Security not subject to transfer restrictions under the Securities Act has been delivered by or on behalf of the Company. 
  
 “Rules and Regulations” means the published rules and
regulations of the Commission promulgated under the Securities Act or the Exchange Act, as in effect at any relevant time. 
  
 “Securities Act” means the United States Securities Act of 1933, as amended. 
  
 “Security” shall mean a Share. 
  
 “Shelf Registration” means a registration effected pursuant
to Section 2 hereof. 
  
 “Shelf Registration
Statement” means a “shelf” registration statement filed under the Securities Act providing for the registration of the resale of, on a continuous or delayed basis by the holders of, all of the Registrable Securities pursuant to
Rule 415 under the Securities Act and/or any similar rule that may be adopted by the Commission, filed by the Company pursuant to the provisions of Section 2 of this Agreement, including the Prospectus contained therein, any amendments and
supplements to such registration statement, including post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement. 
  
 “Subscription Agreement” means the Subscription Agreement, dated as of the date hereof, between the Company
and the Purchasers. 
  

 3 

 “underwriter” means any underwriter of Registrable Securities in connection with an
offering thereof under a Shelf Registration Statement. 
  
 2.
Shelf Registration. 
  
 (a) The Company shall, (1) use its
reasonable best efforts to file with the Commission a Shelf Registration Statement covering to the offer and sale of the Registrable Securities by or on behalf of the Electing Holders on or prior to the Filing Deadline Date and (2) use its
reasonable best efforts to cause such Shelf Registration Statement to be declared effective promptly thereafter; provided, however, that no holder shall be entitled to be named as a selling securityholder in the Shelf Registration Statement
or to use the Prospectus for resales of Registrable Securities unless such holder is an Electing Holder. The Shelf Registration Statement shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable
Securities on Form S-3, in which case such registration shall be on another appropriate form for such purpose) and shall contain (except if otherwise required pursuant to written comments received from the Commission upon a review of such Shelf
Registration Statement) the “Plan of Distribution” attached hereto as Annex A. 
  
 (b) If such Shelf Registration Statement covering the Registrable Securities is not filed with the Commission on or prior to the Filing Deadline Date,
then, notwithstanding any other provision in this Agreement, the Company will make pro rata payments to each Purchaser, as liquidated damages and not as a penalty, in an amount per 30-day period equal to 1.0% (or pro rata portion thereof if the
period is less than 30 days) of the aggregate amount paid by such Purchaser on the Closing Date to the Company for the Shares for the period from the Filing Deadline Date to the date on which such Shelf Registration Statement is filed. No such
payments shall be payable in respect of any Securities that are not Registrable Securities. Such payments shall be made to each Purchaser in cash not later than three Business Days following the end of each 30-day period. Such payments shall
constitute the holders’ exclusive remedy for such events. 
  
 (c) The Company shall use its reasonable best efforts to keep the Shelf Registration Statement continuously effective in order to permit the Prospectus to be usable by holders for resales of Registrable Securities until the earlier of (A)
the sale under the Shelf Registration Statement of all the Registrable Securities registered thereunder and (B) all of the Securities ceasing to be Restricted Securities (such period being referred to herein as the “Effectiveness Period”).

  
 3. Registration Procedures. In connection with the
Shelf Registration Statement, the following provisions shall apply: 
  
 (a) The Company shall mail the Notice and Questionnaire to the holders of Registrable Securities. No holder shall be entitled to be named as a selling securityholder in the Shelf Registration Statement as of the Effective Time, and no
holder shall be entitled to use the Prospectus for resales of Registrable Securities at any time unless such holder has returned a completed and signed Notice and Questionnaire to the Company by the deadline for response set forth therein;
provided, however, holders of Registrable 
  

 4 

 Securities shall have at least 10 calendar days from the date on which the Notice and Questionnaire is first mailed to
such holders to return a completed and signed Notice and Questionnaire to the Company. The term “Electing Holder” shall mean any holder of Registrable Securities that has returned a completed and signed Notice and Questionnaire to the
Company in accordance with Section 3(a) hereof. 
  
 (b) The
Company shall, if requested by an Electing Holder, furnish to each Electing Holder, within a reasonable period of time prior to filing with the Commission, a copy of such Shelf Registration Statement, and shall furnish to such holders, within a
reasonable period of time prior to the filing of any amendment or supplement to the Prospectus, a copy of such amendment or supplement and shall reflect in each such document when so filed with the Commission such comments as such holders reasonably
may propose; provided, however, that the Company shall make the final decision as to the form and content of each such document and provided further that the Company may omit from the copy of the Shelf Registration Statement provided to each
Electing Holder information which the Company believes would constitute material and non-public information. 
  
 (c) From the date hereof until the end of the Effectiveness Period, the Company shall (subject to Section 3(i) below) promptly take such action as may be
necessary so that (i) each of the Shelf Registration Statement and any amendment thereto and the Prospectus and any amendment or supplement thereto (and each report or other document incorporated by reference therein in each case) complies in all
material respects with the Securities Act and the Exchange Act and the respective rules and regulations thereunder, (ii) each of the Shelf Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading and (iii) each of the Prospectus and
any amendment or supplement to the Prospectus does not at any time during the Effectiveness Period include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. 
  
 (d)
The Company shall promptly (but in any event no later than three Business Days after such occurrence) advise each Electing Holder, and shall confirm such advice in writing if so requested by any such holder (which notice shall to the extent deemed
appropriate by the Company, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made): 
  
 (i) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness
of the Shelf Registration Statement or the initiation of any proceedings for such purpose; 
  
 (ii) of the receipt by the Company of any notification with respect to the suspension of the qualification of the securities included in
the Shelf Registration Statement for sale in any jurisdiction or the initiation of any proceeding for such purpose; and 
  

 5 

 (iii) if changes in the Shelf Registration Statement or the Prospectus are required in
order that the Shelf Registration Statement and Prospectus do not contain an untrue statement of a material fact and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of the
Prospectus, in light of the circumstances under which they were made) not misleading. 
  
 (e) The Company shall use its reasonable best efforts to prevent the issuance, and if issued to obtain the withdrawal, of any order suspending the effectiveness of the Shelf Registration Statement at the earliest
possible time. 
  
 (f) The Company shall furnish to each
requesting Electing Holder, without charge, at least one copy of the Shelf Registration Statement and all post-effective amendments thereto, and, if such holder so requests in writing, all reports, other documents and exhibits that are filed with or
incorporated by reference in the Shelf Registration Statement. 
  
 (g) The Company shall, during the Effectiveness Period, deliver to each Electing Holder, without charge, as many copies of the Prospectus (including each preliminary Prospectus) and any amendment or supplement thereto as such Electing
Holder may reasonably request; and the Company consents (except during the continuance of any event described in Section 3(d) above) to the use of the Prospectus and any amendment or supplement thereto by each of the Electing Holders in connection
with the offering and sale of the Registrable Securities covered by the Prospectus and any amendment or supplement thereto during the Effectiveness Period. 
  
 (h) Prior to any offering of Registrable Securities pursuant to the Shelf Registration Statement, the Company shall use its reasonable best efforts to
either (I) cause such securities to be included for listing on the Nasdaq National Market or (II) (a) register or qualify the registration or qualification of such Registrable Securities for offer and sale under the securities or “blue
sky” laws of such jurisdictions within the United States as any Electing Holder may reasonably request, (b) keep such registrations or qualifications in effect and comply with such laws so as to permit the continuance of offers and sales in
such jurisdictions for so long as may be necessary to enable any Electing Holder or underwriter, if any, to complete its distribution of Registrable Securities pursuant to the Shelf Registration Statement, and (c) take any and all other actions
necessary or advisable to enable the disposition in such jurisdictions of such Registrable Securities; provided, however, that in no event shall the Company be obligated to (A) qualify as a foreign corporation or as a dealer in
securities in any jurisdiction where it would not otherwise be required to so qualify but for this Section 3(h) or (B) file any general consent to service of process in any jurisdiction where it is not as of the date hereof so subject. 

 
 (i) Upon the occurrence of any fact or event contemplated by paragraph
3(d)(ii) above, the Company shall (subject to the next sentence) promptly prepare a post-effective amendment or supplement to the Shelf Registration Statement or the Prospectus, or any document incorporated therein by reference, or file any other
required document so that, as thereafter delivered to purchasers of the Registrable Securities included 
  

 6 

 therein, the Prospectus will not include an untrue statement of a material fact or omit to state any material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. If the Company notifies the Electing Holders in accordance with clauses (i) through (iii) of paragraph 3(d) above to suspend the
use of the Prospectus until the requisite changes to the Prospectus have been made, then each Electing Holder shall suspend the use of the Prospectus until (i) such Electing Holder has received copies of the supplemented or amended Prospectus
contemplated by the preceding sentence or (ii) such Electing Holder is advised in writing by the Company that the use of the Prospectus may be resumed and has received copies of any additional or supplemental filings that are incorporated by
reference in the Prospectus. Notwithstanding the foregoing, the Company may suspend the use of the Prospectus and shall not be required to amend or supplement the Shelf Registration Statement, any related Prospectus or any document incorporated by
reference, for a reasonable period of time, but not to exceed an aggregate of 45 trading days in any 12-month period, if and so long as the Delay Conditions exist. 
  
 (j) The Company will use its reasonable best efforts to cause the Common Stock to be listed on the Nasdaq National Market
or other stock exchange or trading system, if any, on which the Common Stock primarily trades on or prior to the Effective Time. 
  
 (k) Subject to this Agreement, the Company shall use its reasonable best efforts to take all other steps necessary to effect the registration, offering
and sale of the Registrable Securities covered by the Shelf Registration Statement contemplated hereby. 
  
 4. Registration Expenses. All fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by
it whether or not any Shelf Registration Statement is filed or becomes effective and whether or not any securities are issued or sold pursuant to any Shelf Registration Statement. The fees and expenses referred to in the foregoing sentence shall
include (i) all registration and filing fees with respect to filings required to be made with the National Association of Securities Dealers, Inc., (ii) fees and expenses incurred for compliance with securities or Blue Sky laws up to $5,000 for all
holders of Registrable Securities, (iii) printing expenses (including without limitation expenses of printing certificates for Registrable Securities), (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company desires such insurance, and (vi) fees and expenses of all other persons retained by the Company. In addition, the Company shall pay its internal expenses (including without limitation all salaries and expenses of its officers and
employees performing legal or accounting duties), the expense of any annual audit, and the fees and expenses incurred in connection with the listing of the Securities on the Nasdaq National Market. Notwithstanding the foregoing or anything in this
Agreement to the contrary, each holder of the Registrable Securities being registered shall pay all commissions and underwriting discounts and commissions with respect to any Registrable Securities sold by it and the fees and disbursements of any
counsel or other advisors or experts retained by such holders (severally or jointly). 
  

 7 

 5. Indemnification and Contribution. 
  
 (a) Indemnification by the Company. 
  
 (i) The Company shall indemnify and hold harmless each Electing Holder and each underwriter, selling agent
or other securities professional, if any, which facilitates the disposition of Registrable Securities, and each of their respective officers and directors and each person who controls such Electing Holder, underwriter, selling agent or other
securities professional within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (each such person being sometimes referred to as an “Indemnified Person”) against any losses, claims, damages or liabilities,
joint or several, to which such Indemnified Person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or
alleged untrue statement of a material fact contained in any Shelf Registration Statement or any Prospectus contained therein or furnished by the Company to any Indemnified Person, or any amendment or supplement thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, and 
  
 (ii) the Company hereby agrees to reimburse such
Indemnified Person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable to any such
Indemnified Person in any such case under Section 5(a)(i) above or this Section 5(a)(ii) to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or
alleged omission made in such Shelf Registration Statement or Prospectus, or amendment or supplement thereto, in reliance upon and in conformity with written information relating to such Indemnified Person furnished to the Company by or on behalf of
such Indemnified Person expressly for use therein; provided, further, however, that the foregoing indemnity agreement with respect to any Prospectus shall not inure to the benefit of any Indemnified Person who failed to deliver a final Prospectus or
an amendment or supplement thereto (provided by the Company to the several Indemnified Persons in the requisite quantity and on a timely basis to permit proper delivery on or prior to the relevant transaction date) to the person asserting any
losses, claims, damages and liabilities and judgments caused by any untrue statement or alleged untrue statement of a material fact contained in any Prospectus, or caused by any omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, if such material misstatement or omission or alleged material misstatement or omission was cured in the final
Prospectus or an amendment or supplement thereto. 
  

 8 

 (b) Indemnification by the Holders. Each Electing Holder agrees, as a consequence of the
inclusion of any of such holder’s Registrable Securities in any Shelf Registration Statement, severally and not jointly, to (i) indemnify and hold harmless the Company, its directors, officers who sign such Shelf Registration Statement and each
person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, claims, damages or liabilities to which the Company or such other persons may become
subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in
such Shelf Registration Statement or Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information
relating to such holder furnished to the Company by or on behalf of such holder expressly for use therein and (ii) reimburse the Company and its directors and officers who sign such Shelf Registration Statement for any legal or other expenses
reasonably incurred by the Company and such directors and officers in connection with investigating or defending any such action or claim as such expenses are incurred. 
  
 (c) Notices of Claims, Etc. Promptly after receipt by an indemnified party under subsection (a) or (b) of this
Section 5 of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 5, notify such indemnifying party in writing of the commencement
thereof; but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to any indemnified party under this Section 5 unless the indemnifying party is materially prejudiced by the delay. In case any
such action shall be brought against any indemnified party and it shall notify an indemnifying party of the commencement thereof, such indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with
any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after
notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, such indemnifying party shall not be liable to such indemnified party under this Section 5 for any legal expenses of other counsel or any
other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the written consent of the indemnified party,
which consent will not be unreasonably withheld, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be
sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising
out of such action or claim and (ii) does not include a statement as to, or an admission of, fault, culpability or a failure to act, by or on behalf of any indemnified party. 
  

 9 

 6. Miscellaneous. 
  
 (a) Remedies. The Company acknowledges and agrees that any failure by the Company to comply with its obligations
under this Agreement may result in material irreparable injury to the Purchasers or the holders of Registrable Securities for which there is no adequate remedy at law, that it will not be possible to measure damages for such injuries precisely and
that, in the event of any such failure, the Purchasers or any holder of Registrable Securities may obtain such relief as may be required to specifically enforce the Company’s obligations hereunder. The Company further agrees to waive the
defense in any action for specific performance that a remedy at law would be adequate. 
  
 (b) Amendments and Waivers. The provisions of this Agreement may not be amended, modified or supplemented, and waivers or consents to or departures from the provisions hereof may not be given unless the Company
has obtained the written consent of holders of a majority of the Registrable Securities held by Electing Holders (excluding Registrable Securities held by the Company or its Affiliates). 
  
 (c) Notices. All notices and other communications provided for or permitted hereunder shall be given as provided in
the Subscription Agreement. 
  
 (d) Counterparts. This
Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

  
 (e) Headings. The headings in this agreement are for
convenience of reference only and shall not limit or otherwise affect the meaning, construction or interpretation hereof. 
  
 (f) Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance with the laws of
the State of California without giving effect to provisions relating to conflicts of law to the extent the application of the laws of another jurisdiction would be required thereby. If a Purchaser shall commence a proceeding against the Company, or
if the Company shall commence a proceeding against a Purchaser, to enforce any provisions of this Agreement, then the prevailing party in such proceeding shall be reimbursed by the other party for its attorney’s fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such proceeding. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of California located in Orange County and the United
States District Court for the Southern District of California for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with
any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of
any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably
waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES 
  

 10 

 HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
  
 (g) Severability. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality
and enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired or affected thereby, it being intended that all of the rights and privileges of the parties hereto shall be
enforceable to the fullest extent permitted by law. 
  
 (h)
Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject
matter hereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein, with respect to the registration rights granted with respect to the Registrable Securities. This Agreement supersedes
all prior agreements and understandings between the parties with respect to such subject matter. 
  

 11 

 Please confirm by signing in the space provided below that the foregoing correctly sets forth the
agreement between the Company and you. 
  

			
	Very truly yours,
	
	SERACARE LIFE SCIENCES, INC.
		
	By:	 	  

	 	 	Name:
	 	 	Title:
	Date:	 	 July 9, 2004

  

 12 

 REGISTRATION RIGHTS AGREEMENT SIGNATURE PAGE 
  

					
	Accepted and Agreed
	  

	Name (Print)	 	 
		
	By:	 	  

	 	 	Name:	 	  

	 	 	Title:	 	  

	Date:	 	 	 	  

	Address:	 	 	 	  

	 	 	 	 	  

	 	 	 	 	  

	Telephone:	 	 	 	  

	Facsimile:	 	 	 	  

  

 13 

 Annex A 
  
 Plan of Distribution 
  
 The Selling Stockholders and any of their pledgees, donees, assignees and successors-in-interest may, from time to time, sell any or all of their shares
of Common Stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholders may use any one or more of the following methods
when selling shares: 
  

	•	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	•	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

  

	•	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	•	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	•	privately negotiated transactions; 

  

	•	to cover short sales made after the date that this Registration Statement is declared effective by the Securities and Exchange Commission; 

  

	•	broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	•	a combination of any such methods of sale; and 

  

	•	any other method permitted pursuant to applicable law. 

  
 The Selling Stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus. 
  
 Broker-dealers engaged by the Selling Stockholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The
Selling Stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. 
  
 The Selling Stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters” within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be 
  

 14 

 underwriting commissions or discounts under the Securities Act. Discounts, concessions, commissions and similar selling
expenses, if any, that can be attributed to the sale of Securities will be paid by the Selling Stockholder and/or the purchasers. 
  
 Each Selling Stockholder has represented and warranted to the Company that it does not have any agreement or understanding, directly or indirectly, with
any person to distribute the Common Stock. The Company has advised each Selling Stockholder that it may not use shares registered on this Registration Statement to cover short sales of Common Stock prior to the date on which this Registration
Statement shall have been declared effective by the Securities and Exchange Commission. If a Selling Stockholder uses this prospectus for any sale of the Common Stock, it will be subject to the prospectus delivery requirements of the Securities Act.
The Selling Stockholders will be responsible to comply with the applicable provisions of the Securities Act and Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder promulgated, including without limitation,
Regulation M, as applicable to such Selling Stockholders in connection with resales of their respective shares under this Registration Statement. 
  
 The Selling Stockholders may only sell the Common Stock if such sales are made in satisfaction of the requirements for exemption from registration or
qualification under the applicable laws of each applicable state. The Selling Stockholders may not offer or sell the Common Stock in any state where the offer or sale is not permitted. The Selling Stockholders will be responsible for compliance with
any applicable state laws governing the resale of the Common Stock. 
  
 The Company is required to pay all fees and expenses incident to the registration of the shares, but the Company will not receive any proceeds from the sale of the Common Stock. The Company has agreed to indemnify the Selling Stockholders
against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. 
  

 15 

 EXHIBIT A 
  

SeraCare Life Sciences, Inc. 
  
 Notice of Registration Statement 
 and 

 Selling Securityholder Questionnaire 
  
 (Date) 
  
 Reference is hereby made to the Registration Rights Agreement (the “Registration Rights Agreement”) between SeraCare Life Sciences, Inc. (the
“Company”) and the Purchasers named therein. Pursuant to the Registration Rights Agreement, the Company intends to file with the United States Securities and Exchange Commission (the “Commission”) a registration statement on Form
S-3 (the “Shelf Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of shares of the Company’s common stock, no par value (the
“Securities”). A copy of the Registration Rights Agreement is attached hereto. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. 
  
 In order to have Registrable Securities included in the Shelf Registration
Statement, this Notice of Registration Statement and Selling Securityholder Questionnaire (“Notice and Questionnaire”) must be completed, executed and delivered to the Company’s counsel at the address set forth herein for receipt on
or before [Insert Deadline for Response]. Beneficial owners of Registrable Securities who do not complete, execute and return this Notice and Questionnaire by such date (i) will not be named as selling securityholders in the Shelf Registration
Statement and (ii) may not use the Prospectus forming a part thereof for resales of Registrable Securities. 
  
 Certain legal consequences arise from being named as a selling securityholder in the Shelf Registration Statement and related Prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Shelf Registration Statement and related
Prospectus. 
  
 The term “Registrable Securities”
is defined in the Registration Rights Agreement to mean all or any portion of the Securities; provided, however, that a security ceases to be a Registrable Security when it is no longer a Restricted Security. 
  
 The term “Restricted Security” is defined in the
Registration Rights Agreement to mean any Security except any such Security that (i) the resale of which has been registered pursuant to an effective registration statement under the Securities Act and sold in a manner contemplated by the Shelf
Registration Statement, (ii) has been transferred in compliance with 
  

 16 

 Rule 144 under the Securities Act (or any successor provision thereto) or is transferable pursuant to paragraph (k) of
such Rule 144 (or any successor provision thereto), or (iii) has otherwise been transferred and a new Security not subject to transfer restrictions under the Securities Act has been delivered by or on behalf of the Company. 
  
 ELECTION 
  
 The undersigned holder (the “Selling Securityholder”) of Registrable Securities hereby elects to include in the
Shelf Registration Statement the Registrable Securities beneficially owned by it and the Registrable Securities listed below in Item (3). The undersigned, by signing and returning this Notice and Questionnaire, agrees to be bound with respect to
such Registrable Securities by the terms and conditions of this Notice and Questionnaire and the Registration Rights Agreement, including without limitation Section 5 of the Registration Rights Agreement as if the undersigned Selling Securityholder
were an original party thereto. 
  
 The Selling Securityholder
hereby provides the following information to the Company and represents and warrants that such information is accurate and complete: 
  
 QUESTIONNAIRE 
  
 Certain capitalized terms used in this Questionnaire are defined in Appendix l attached hereto. Capitalized terms used in this Questionnaire but not
defined in Appendix 1 have the meanings given to them in the accompanying letter. 
  

					
	(1)	 	(a)	 	Full legal name of Selling Securityholder:
			
	 	 	 	 	____________________________________________________________________________________
			
	 	 	 	 	(i) Is such Selling Securityholder a:
			
	 	 	 	 	[    ] Corporation             [    ] General Partnership
			
	 	 	 	 	[    ] Individual                [    ] Limited Partnership
			
	 	 	 	 	[    ] Other (please specify:
                                       
 )
			
	 	 	 	 	(ii) In what state is such Selling Securityholder organized or domiciled?
			
	 	 	 	 	  
 ___________________________________

		
	 	 	(b) Full legal name of Registered Holder (if not the same as in (a) above) of Registrable Securities listed in Item (4) below:
		
	 	 	__________________________________________________________________
		
	(2)	 	Address for Notices to Selling Securityholder:
			
	 	 	 	 	___________________________________
			
	 	 	 	 	  
 ___________________________________

			
	 	 	 	 	  
 ___________________________________

  

 17 

			
	Telephone:	 	___________________________________
		
	Fax:	 	___________________________________
		
	Contact Person:	 	___________________________________

  

			
	(3)	 	Beneficial Ownership of Securities by Another Entity or Individual:
		
	 	 	(a) Is another entity or individual the Beneficial Owner of any Securities?
		
	 	 	[    ] No (skip questions (b)-(e) below)
		
	 	 	[    ] Yes (answer questions (b)-(e) below)
		
	 	 	(b) What is the full legal name of such Beneficial Owner?
		
	 	 	_____________________________________________________________
		
	 	 	(c) Is such Beneficial Owner a:
		
	 	 	[    ] Corporation             [    ] General Partnership
		
	 	 	[    ] Individual                [    ] Limited Partnership
		
	 	 	[    ] Other (please
specify:                                      
  )
		
	 	 	(d) In what state is such Beneficial Owner organized or domiciled?
		
	 	 	_____________________________________________________________
		
	 	 	(e) Please provide the name, address and telephone number of a contact person for such Beneficial Owner.
		
	 	 	____________________________________________________________
	 	 	  
 ____________________________________________________________

	 	 	  
 ____________________________________________________________

	 	 	  
 ____________________________________________________________

		
	(4)	 	Beneficial Ownership of Securities:
		
	 	 	Except as set forth below in this Item (4), the undersigned is not a Beneficial Owner of any Securities.
		
	 	 	(a) Number of Registrable Securities (as defined in the Registration Rights Agreement) Beneficially Owned:
                                        
         CUSIP No(s). of such Registrable Securities:
                                        
        
		
	 	 	(b) Number of Securities other than Registrable Securities Beneficially Owned:
		
	 	 	_____________________________________________________________
		
	 	 	CUSIP No(s). of such other Securities:
	 	 	______________________
		
	 	 	(c) Number of Registrable Securities that the undersigned wishes to be included in the Shelf Registration Statement:
		
	 	 	                                       
           CUSIP No(s). of such Registrable Securities to be included in the Shelf Registration Statement:
  

_____________________________________________________________

  

 18 

 (5) Relationships with the Company: 
  
 Except as set forth below, neither the Selling Securityholder nor any of
its Affiliates, officers, directors or principal equity holders (5% or more) has held any position or office or has had any other Material Relationship with the Company (or its predecessors or Affiliates) during the past three years. 

 
 State any exceptions here: 
  
 (6) Full Legal Name of Natural Control Person (which means a natural person who directly or
indirectly alone or with others has power to vote or dispose of the securities covered by the questionnaire): 
 ____________________________________________________________________________ 
  

							
	(7)	 	Broker-Dealer Status:
			
	 	 	(a)	 	Are you a broker-dealer?
			
	 	 	 	 	 Yes   ̈         No   ̈

			
	 	 	Note:	 	If yes, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
			
	 	 	(b)	 	Are you an affiliate of a broker-dealer?
			
	 	 	 	 	 Yes   ̈         No   ̈

			
	 	 	(c)	 	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the purchase of the
Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
			
	 	 	 	 	 Yes   ̈         No   ̈

			
	 	 	Note:	 	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

  

 19 

 By signing below, the Selling Securityholder acknowledges that it understands its obligation to comply,
and agrees that it will comply, with the provisions of the Exchange Act and the rules and regulations thereunder, particularly Regulation M. The Selling Securityholder also acknowledges that it understands that the answers to this Questionnaire are
furnished for use in connection with the Registration Statement and any amendments or supplements thereto filed with the SEC pursuant to the Securities Act of 1933, as amended. 
  
 In the event that the Selling Securityholder transfers all or any portion of the Registrable Securities listed in Item (3)
above after the date on which such information is provided to the Company, the Selling Securityholder agrees to notify the transferee(s) at the time of the transfer of its rights and obligations under this Notice and Questionnaire and the
Registration Rights Agreement. 
  
 By signing below, the Selling
Securityholder consents to the disclosure of the information contained herein in its answers to Items (1) through (7) above and the inclusion of such information in the Shelf Registration Statement and related Prospectus. The Selling Securityholder
understands that such information will be relied upon by the Company in connection with the preparation of the Shelf Registration Statement and related Prospectus. 
  
 The Selling Securityholder acknowledges that material misstatements and omissions of material facts in the Registration
Statement and any amendments or supplement thereto may give rise to civil and criminal liabilities to the Company and to each officer and director of the Company signing the Registration Statement and to other persons signing such document. As a
result, in accordance with the Selling Securityholder’s obligation under Section 3(a) of the Registration Rights Agreement to provide such information as may be required by law for inclusion in the Shelf Registration Statement, the Selling
Securityholder agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein which may occur subsequent to the date hereof at any time while the Shelf Registration Statement remains in effect. All notices
hereunder shall be made in accordance with the Registration Rights Agreement as follows: 
  
 (i) to the Company: 
  
 SeraCare Life Sciences, Inc. 
 1935 Avenida del Oro, Suite F 
 Oceanside, CA 92056 
 Attention: President 
  
 (ii) with a copy to:

  
 O’Melveny & Myers, LLP 

114 Pacifica, Suite 100 
 Irvine, CA 92618-3318 
 Attention: Andor D. Terner, Esq. 
  
 I confirm that, to the best of my knowledge and belief, the foregoing
statements (including without limitation the answers to this Questionnaire) are correct. 
  

 20 

 IN WITNESS WHEREOF, the undersigned, by authority duly given, has caused this Notice and Questionnaire to
be executed and delivered either in person or by its duly authorized agent. 
  
 Dated:                      
  

			
	__________________________________________
	Selling Securityholder
	
	 (Print/type full legal name of beneficial owner of Registrable Securities)

		
	By:	 	  

	 	 	Name:
	 	 	Title:

  
 PLEASE RETURN THE COMPLETED AND
EXECUTED NOTICE AND QUESTIONNAIRE FOR RECEIPT ON OR BEFORE [DEADLINE FOR RESPONSE] TO THE COMPANY’S COUNSEL AT: 
  
 O’Melveny & Myers, LLP 
 610 Newport Center Drive, Suite 1700 
 Newport Beach, CA 92660 
 Attention: Megan Gess, Esq. 
  

 21 

 APPENDIX I 
  

DEFINITIONS 
  
 For the purpose of this Questionnaire, the following definitions apply: 
  
 1. Affiliate. As used in Questions 1 - 6, a person is an “Affiliate” of a person if such person controls,
is controlled by, or is under common control with, another person. Please assume that an “Affiliate” of the Company includes without limitation, any 5% stockholder of the Company (including any person who owns, controls, or holds or holds
an option to acquire, and has the power to vote, 5% or more of the Company’s outstanding voting securities). “Control” is the possession, directly or indirectly, of the power to direct or cause the direction of the management and
policies of an entity, whether through the ownership of voting securities, by contract or otherwise. 
  
 As used in Question 7 of this Questionnaire, an “affiliate” of an NASD member has the following meaning: 
  
 (1) a company which controls, is controlled by or is under common control
with a member; 
  
 (2) the term affiliate is presumed to include,
but is not limited to, the following: 
  
 (a) a company will be
presumed to control a member if the company beneficially owns 10% or more of the outstanding voting securities of a member which is a corporation, or beneficially owns a partnership interest in 10% or more of the distributable profits or losses of a
member which is a partnership; 
  
 (b) a member will be presumed
to control a company if the member and persons associated with the member beneficially own (i) 10% or more of the outstanding subordinated debt of a company, (ii) 10% or more of the outstanding voting securities of a company which is a corporation
or (iii) a partnership interest in 10% or more of the distributable profits or losses of a company which is a partnership; 
  
 (c) a company will be presumed to be under common control with a member if: 
  
 (i) the same natural person or company controls both the member and company by beneficially owning 10% or more of the
outstanding voting securities of a member or company which is a corporation, or by beneficially owning a partnership interest in 10% or more of the distributable profits or losses of a member or company which is a partnership; or 
  
 (ii) a person having the power to direct or cause the direction of the
management or policies of the member or the company also has the power to direct or cause the direction of the management or policies of the other entity in question. 
  

 22 

 2. Beneficial Owner. A “Beneficial Owner” of a security includes any person who,
directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power and/or investment power with respect to such security. Voting power includes “the power to vote, or to direct the
voting, of such security” and investment power includes “the power to dispose, or to direct the disposition, of such security.” 
  
 A person is also a Beneficial Owner of a security if he has the right to acquire beneficial ownership of such security, at any time within sixty days,
including but not limited to, any right to acquire through: (a) the exercise of an option, warrant or right, (b) the conversion of a convertible security, (c) the power to revoke a trust, discretionary account or similar arrangement, or (d) the
automatic termination of a trust, discretionary account or similar arrangement; provided, however, that if the acquisition of an option, warrant, right, convertible security or power described in (a), (b) or (c) is for the purpose of maintaining or
obtaining control over the issuer of the security, the holder of the option, warrant, right, convertible security or power shall, immediately upon such acquisition and regardless of when it is exercisable, be deemed a beneficial owner of the
underlying securities. 
  
 The possession of the legal power to
vote and/or direct the disposition of securities, absent unusual circumstances, will be sufficient to confer beneficial ownership. Such power may be held directly, or indirectly, through one or more controlled entities. 
  
 3. Material Relationship. The term “material relationship”
has not been defined by the Securities and Exchange Commission (the “SEC”). The SEC, however, is likely to construe as material any relationship which tends to impact arm’s length bargaining in dealings with a company, whether arising
from a close business connection, family relationship, a relationship of control or otherwise. For example, you should conclude that you have such a relationship with any organization of which you own, directly or indirectly, 10% more of the
outstanding voting stock, or in which you have some other substantial interest, and with any person or organization with whom you have, or with whom any relative (or any other person or organization as to which you have any of the foregoing other
relationships) has, a contractual relationship. 
  
 4.
Member. Rule 0120 of the NASD’s Rules of Fair Practice defines the term “member” to mean any individual, partnership, corporation or other legal entity admitted to membership in the NASD, and Article l of the NASD’s
By-Laws defines the term “person associated with a member” to mean every sole proprietor, partner, officer, director, or branch manager of any member, or any natural person occupying a similar status or performing similar functions, or any
natural person engaged in the investment banking or securities business who is directly or indirectly controlling or controlled by such member (for example, any employee), whether or not such person is registered or exempt from registration with the
NASD. 
  

 23 

 Exhibit B 
  

Wire Transfer Instructions 
  
 Wells Fargo Bank 
 ABA # 121000248 
 Cr: Corporate Trust Clearing 
 A/C# 1038377 
 FFC: Power SeraCare Life/First Equity Cap Esc, A/C #16110200 
 Attn: Kimberly
A. Vann, (213) 614-3352 
  

 Exhibit C 
  

Form of Escrow Agreement 
  
 [Attached Hereto] 
  

 SERACARE LIFE SCIENCES, INC. 
  
 Registration Rights Agreement 
  

			
	 	  	 List of Purchasers

	1.	  	Marshall M. Becker
	2.	  	Stanley S. Becker
	3.	  	Murray Blitstein
	4.	  	Anthony Cappiello
	5.	  	Castlerigg Master Investments Ltd.
	6.	  	Catalysis Partners, LLC
	7.	  	Scott DeGhetto
	8.	  	EL Equities, LLC
	9.	  	Bernard R. Feingold
	10.	  	Robert Graifman
	11.	  	Michael Groveman
	12.	  	Geoffrey M. Haar
	13.	  	William M. Hitchcock
	14.	  	Linda Jacobson
	15.	  	James G. Kreissman
	16.	  	Robert S. Krieger
	17.	  	Joan B. Levine
	18.	  	Kenneth R. Levine
	19.	  	J.E. McConnaughy Jr.

			
	 	  	 List of Purchasers

	 20.
	  	New Dimensions Trading Limited
	 21.
	  	Provco Ventures I, LP
	 22.
	  	Stager Partners LP
	 23.
	  	The Lincoln Fund, L.P.
	 24.
	  	Joshua Winkler

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]